Insider Selling: Glaukos (NYSE:GKOS) Director Sells $475,000.00 in Stock

Glaukos Corporation (NYSE:GKOS) Director Gilbert Kliman sold 2,500 shares of Glaukos stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $190.00, for a total value of $475,000.00. Following the completion of the sale, the director directly owned 37,406 shares in the company, valued at $7,107,140. This represents a 6.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Glaukos Stock Up 0.4%

NYSE GKOS opened at $185.66 on Friday. The business has a fifty day moving average price of $157.38 and a 200 day moving average price of $131.62. Glaukos Corporation has a one year low of $73.16 and a one year high of $191.62. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.46 and a current ratio of 5.04. The company has a market cap of $10.95 billion, a P/E ratio of -57.13 and a beta of 0.78.

Glaukos (NYSE:GKOS) last announced its quarterly earnings data on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.07. Glaukos had a negative return on equity of 6.37% and a negative net margin of 30.68%.The company had revenue of $185.61 million for the quarter, compared to analyst estimates of $150.93 million. During the same quarter last year, the firm posted ($0.24) EPS. The firm’s revenue for the quarter was up 49.6% on a year-over-year basis. Research analysts anticipate that Glaukos Corporation will post -0.32 EPS for the current fiscal year.

Trending Headlines about Glaukos

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: BTIG Research raised its price target to $202 from $193 and maintained a “Buy” rating, implying additional upside from the referenced share price. The move reinforces bullish sentiment among analysts. BTIG price target report
• Positive Sentiment: Zacks Research lifted its FY2026 EPS forecast to a loss of $0.43 from a loss of $0.65, its Q3 2026 estimate to a loss of $0.13 from $0.16, and its Q4 estimate to positive $0.03 from a loss of $0.02. The revisions suggest improving near-term earnings trends.
• Positive Sentiment: Zacks also raised its FY2027 EPS estimate to $0.45 from $0.38 and its FY2028 forecast to $1.70 from $1.56. Several later-quarter estimates were increased, pointing to expectations that Glaukos will become increasingly profitable as its products scale.
• Positive Sentiment: Momentum in the iDose TR glaucoma implant and the Epioxa launch is reportedly driving record growth, higher 2026 guidance and expansion of Glaukos’ ophthalmology platform. Zacks growth outlook article
• Neutral Sentiment: Glaukos recently reported revenue of $185.6 million, up 49.6% year over year, while its $0.14 quarterly loss was narrower than expected. However, the company remains unprofitable, and its current-year consensus EPS forecast is still a loss of $0.35.
• Negative Sentiment: Director Gilbert H. Kliman sold 2,500 shares for approximately $475,000 at an average price of $190, reducing his direct ownership by 6.26%. He retained 37,406 shares, so the transaction is a modest negative signal rather than a major change in insider alignment. SEC insider selling filing

Analysts Set New Price Targets

A number of research firms recently weighed in on GKOS. Wall Street Zen upgraded shares of Glaukos from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Stifel Nicolaus increased their price objective on shares of Glaukos from $175.00 to $190.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Wells Fargo & Company raised their target price on shares of Glaukos from $138.00 to $178.00 and gave the stock an “overweight” rating in a research note on Thursday, July 30th. Citigroup boosted their target price on Glaukos from $175.00 to $188.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Finally, BTIG Research upped their price target on Glaukos from $193.00 to $202.00 and gave the company a “buy” rating in a research report on Thursday. Twelve analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $178.08.

Institutional Trading of Glaukos

Hedge funds have recently made changes to their positions in the company. First Horizon Corp raised its position in shares of Glaukos by 1,715.4% during the 4th quarter. First Horizon Corp now owns 236 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 223 shares during the period. Allworth Financial LP acquired a new position in Glaukos in the second quarter valued at approximately $28,000. Los Angeles Capital Management LLC purchased a new position in Glaukos in the fourth quarter worth approximately $28,000. Larson Financial Group LLC grew its position in Glaukos by 62.0% in the fourth quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock worth $39,000 after acquiring an additional 132 shares during the period. Finally, Parallel Advisors LLC increased its stake in Glaukos by 159.2% during the first quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 226 shares during the last quarter. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.